MX2025001237A - Celulas modificadas geneticamente con expresion genica reducida para mitigar el reconocimiento de celulas inmunitarias - Google Patents

Celulas modificadas geneticamente con expresion genica reducida para mitigar el reconocimiento de celulas inmunitarias

Info

Publication number
MX2025001237A
MX2025001237A MX2025001237A MX2025001237A MX2025001237A MX 2025001237 A MX2025001237 A MX 2025001237A MX 2025001237 A MX2025001237 A MX 2025001237A MX 2025001237 A MX2025001237 A MX 2025001237A MX 2025001237 A MX2025001237 A MX 2025001237A
Authority
MX
Mexico
Prior art keywords
cells
engineered
express
gene expression
immune cell
Prior art date
Application number
MX2025001237A
Other languages
English (en)
Inventor
Cesar Adolfo Sommer
Hsin - Yuan CHENG
Barbra Johnson Sasu
Original Assignee
Allogene Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allogene Therapeutics Inc filed Critical Allogene Therapeutics Inc
Publication of MX2025001237A publication Critical patent/MX2025001237A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En la presente descripción se proporcionan células inmunitarias modificadas genéticamente y poblaciones de estas para su administración a sujetos para tratar el cáncer (por ejemplo, tumores sólidos o tumores líquidos) y otras afecciones. Las células se modifican genéticamente para expresar funcionalmente un nivel reducido de uno o más de CD48, CD58, ICAM-1, RFX5, NLRC5, TAP2, ß2m, TRAC, RFXAP, CIITA y RFXANK. Las células opcionalmente se modifican genéticamente de manera adicional para expresar una o más de una proteína adicional tal como una proteína de unión a antígenos (por ejemplo, un receptor de antígeno quimérico (CAR) o receptor de células T) y/o una proteína de unión a CD70 para dirigirse a células tumorales u otras células dañadas en el sujeto y/o para expresar otros genes a un nivel reducido. También se proporcionan métodos para fabricar y usar las células modificadas genéticamente, composiciones y kits que las comprenden, y métodos para tratar mediante la administración de las células y las composiciones.
MX2025001237A 2022-07-29 2025-01-29 Celulas modificadas geneticamente con expresion genica reducida para mitigar el reconocimiento de celulas inmunitarias MX2025001237A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263393350P 2022-07-29 2022-07-29
US202363509136P 2023-06-20 2023-06-20
PCT/US2023/071188 WO2024026445A1 (en) 2022-07-29 2023-07-28 Engineered cells with reduced gene expression to mitigate immune cell recognition

Publications (1)

Publication Number Publication Date
MX2025001237A true MX2025001237A (es) 2025-03-07

Family

ID=87748241

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025001237A MX2025001237A (es) 2022-07-29 2025-01-29 Celulas modificadas geneticamente con expresion genica reducida para mitigar el reconocimiento de celulas inmunitarias

Country Status (8)

Country Link
US (1) US20240042030A1 (es)
EP (1) EP4562134A1 (es)
JP (1) JP2025525779A (es)
CN (1) CN119654406A (es)
AU (1) AU2023312973A1 (es)
CA (1) CA3261440A1 (es)
MX (1) MX2025001237A (es)
WO (1) WO2024026445A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260005273A (ko) * 2023-04-21 2026-01-09 카이트 파마 인코포레이티드 면역 거부반응의 위험을 감소시키는 동종이계 치료용 세포
WO2025231191A1 (en) * 2024-05-01 2025-11-06 Cargo Therapeutics, Inc. Compositions and methods for allogeneic immune cells

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6011138A (en) 1997-02-20 2000-01-04 Idec Pharmaceuticals Corporation Gamma-1 anti-human CD23 monoclonal antibodies
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
ATE338124T1 (de) 2000-11-07 2006-09-15 Hope City Cd19-spezifische umgezielte immunzellen
CN100574803C (zh) 2001-01-31 2009-12-30 拜奥根Idec公司 免疫调节抗体在治疗肿瘤性疾病中的用途
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
PT1731605E (pt) 2004-03-31 2010-04-14 Int Inst Cancer Immunology Inc Péptidos antigénicos de cancro derivados de wt1
CA3255551A1 (en) 2010-03-26 2025-04-15 Memorial Sloan-Kettering Cancer Center MUC16 ANTIBODIES AND METHODS OF USE
EP2875133B1 (en) 2012-07-17 2018-01-10 Université de Genève Nucleic acids for down-regulation of gene expression
US11077144B2 (en) 2013-05-13 2021-08-03 Cellectis CD19 specific chimeric antigen receptor and uses thereof
CN105940102B (zh) 2013-08-26 2020-02-18 海瑞克·亚柏坎 抗cd30嵌合抗原受体及其用途
US20160152725A1 (en) 2014-02-25 2016-06-02 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide
TWI719942B (zh) 2014-07-21 2021-03-01 瑞士商諾華公司 使用ｃｄ３３嵌合抗原受體治療癌症
BR112017001183A2 (pt) 2014-07-21 2017-11-28 Novartis Ag tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
GB201413335D0 (en) 2014-07-28 2014-09-10 Azotic Technologies Ltd Agricultural methods
WO2016016341A1 (en) 2014-07-29 2016-02-04 Cellectis EGFRvIII SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR CANCER IMMUNOTHERAPY
ES2818103T3 (es) 2015-01-16 2021-04-09 Juno Therapeutics Inc Anticuerpos y receptores de antígenos quiméricos específicos para ROR1
BR112017013981A2 (pt) 2015-01-26 2018-01-02 Cellectis receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
SG11201707538XA (en) 2015-03-17 2017-10-30 Memorial Sloan Kettering Cancer Center Anti-muc16 antibodies and uses thereof
TW201702272A (zh) 2015-05-22 2017-01-16 美國紀念斯隆 凱特琳癌症中心 Ｐｒａｍｅ肽專一性類ｔ細胞受體抗體
WO2017025323A1 (en) 2015-08-11 2017-02-16 Cellectis Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
MX2018004503A (es) 2015-10-15 2019-04-15 Us Health Receptores de antigeno quimerico anti-cd30.
TWI755547B (zh) 2016-01-21 2022-02-21 美商輝瑞股份有限公司 靶向表皮生長因子受體變異體iii之嵌合型抗原受體
IL262061B2 (en) 2016-04-01 2023-03-01 Amgen Inc Chimeric flt-3 receptors and methods of using them
BR112018070948A2 (pt) 2016-04-13 2019-01-29 Orimabs Ltd. anticorpos anti-psma e utilização dos mesmos
ES2979068T3 (es) 2016-07-08 2024-09-24 Crage Medical Co Ltd Anticuerpos para anti-claudina 18A2 y utilización de los mismos
WO2018072025A1 (en) 2016-10-19 2018-04-26 The Governing Council Of The University Of Toronto Cd133-binding agents and uses thereof
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
TWI785009B (zh) 2017-02-14 2022-12-01 美商凱特製藥公司 Ｃｄ７０結合分子及使用彼之方法
SG10202108528QA (en) 2017-06-02 2021-09-29 Pfizer Chimeric antigen receptors targeting flt3
KR20230008269A (ko) 2017-08-07 2023-01-13 엔비이-테라퓨틱스 아게 생체 내 내성이 높은 항체 약물 결합체
CN112020518A (zh) 2018-02-01 2020-12-01 辉瑞公司 靶向cd70的嵌合抗原受体
CN116836297A (zh) 2018-04-12 2023-10-03 上海赛比曼生物科技有限公司 靶向bcma的嵌合抗原受体及其制法和应用
US20210269501A1 (en) 2018-06-25 2021-09-02 The Trustees Of The University Of Pennsylvania Compositions and methods of nkg2d chimeric antigen receptor t cells for controlling triple-negative breast cancer
WO2020010284A1 (en) 2018-07-04 2020-01-09 Cytoimmune Therapeutics, LLC Compositions and methods for immunotherapy targeting flt3, pd-1, and/or pd-l1
US12036242B2 (en) 2018-07-05 2024-07-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. CAR T cells that target B-cell antigens
BR112021001338A2 (pt) 2018-07-26 2021-05-04 TCR2 Therapeutics Inc. composições e métodos para reprogramação de tcr usando proteínas de fusão específicas para o alvo
WO2020095249A1 (en) 2018-11-07 2020-05-14 Crispr Therapeutics Ag Anti-liv1 immune cell cancer therapy
CN109468284A (zh) 2018-11-30 2019-03-15 北京美康基免生物科技有限公司 一种基于cd19和psma的双重嵌合抗原受体基因修饰的免疫细胞及其应用
AU2019397033B2 (en) 2018-12-12 2023-06-29 Kite Pharma, Inc. Chimeric antigen receptors and CAR-T cells and methods of use
CN109680002A (zh) 2019-01-09 2019-04-26 上海怡豪生物科技有限公司 联合msln单链抗体和ccl19杀伤胃癌细胞的car载体及其构建方法和应用
CN109628492A (zh) 2019-01-09 2019-04-16 上海怡豪生物科技有限公司 联合MSLN单链抗体和PD-1mAb杀伤胃癌细胞的CAR载体及其构建方法和应用
SMT202400408T1 (it) 2019-01-16 2024-11-15 Caribou Biosciences Inc Anticorpo umanizzato bcma e cellule bcma-car-t
US11738050B2 (en) 2019-02-01 2023-08-29 Regents Of The University Of Minnesota Compounds binding to fibroblast activation protein alpha
PH12021551720A1 (en) 2019-03-01 2022-03-28 Allogene Therapeutics Inc Dll3 targeting chimeric antigen receptors and binding agents
WO2020186204A1 (en) 2019-03-13 2020-09-17 Ulmert Hans David Staffan Prame binding molecules and uses thereof
EP3969035A4 (en) 2019-05-14 2023-06-21 Werewolf Therapeutics, Inc. SEPARATION UNITS AND METHODS AND THEIR USE
KR102773187B1 (ko) 2019-07-12 2025-02-27 퓨쳐진 바이오파머쓰티컬 (베이징) 코., 엘티디. Cldn18.2 항체 및 이의 용도
MX2022010340A (es) 2020-02-24 2022-09-19 Allogene Therapeutics Inc Celulas t con car de bcma con actividades mejoradas.
CN111363046A (zh) 2020-03-11 2020-07-03 深圳宾德生物技术有限公司 靶向nkg2d的嵌合抗原受体、嵌合抗原受体t细胞及其制备方法和应用
GB202006587D0 (en) * 2020-05-04 2020-06-17 Celyad S A Improved scaffolds for multiplexed inhibitory rna
CA3204417A1 (en) * 2021-01-29 2022-08-04 Allogene Therapeutics, Inc. Knockdown or knockout of one or more of tap2, nlrc5, ?2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products

Also Published As

Publication number Publication date
CA3261440A1 (en) 2024-02-01
CN119654406A (zh) 2025-03-18
JP2025525779A (ja) 2025-08-07
EP4562134A1 (en) 2025-06-04
WO2024026445A1 (en) 2024-02-01
AU2023312973A1 (en) 2025-01-09
US20240042030A1 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
Zhang et al. Challenges and new technologies in adoptive cell therapy
US12263220B2 (en) Compositions and methods for immunotherapy
MX2025001237A (es) Celulas modificadas geneticamente con expresion genica reducida para mitigar el reconocimiento de celulas inmunitarias
JP7546925B2 (ja) 核酸とｃａｒ修飾免疫細胞とを含む治療薬およびその使用
JP6857028B2 (ja) 免疫治療のための組成物および方法
JP6899333B2 (ja) 汎用キラーｔ細胞
Wu et al. HER2-specific chimeric antigen receptor-engineered natural killer cells combined with apatinib for the treatment of gastric cancer
WO2020163365A3 (en) Combination gene targets for improved immunotherapy
JP2017525385A (ja) 細胞治療物質としてのｃａｒ発現ｎｋ−９２細胞
Aranda et al. Trial Watch: Adoptive cell transfer for anticancer immunotherapy
JP2024097924A (ja) 抗ｐｔｋ７免疫細胞癌療法
MX2023008809A (es) ATENUACIÓN O INACTIVACIÓN DE UNO O MÁS DE TAP2, NLRC5, ß2M, TRAC, RFX5, RFXAP Y RFXANK PARA MITIGAR EL RECONOCIMIENTO DE CÉLULAS T DE PRODUCTOS CELULARES ALOGÉNICOS.
JP2022513586A (ja) 抗ｌｉｖ１免疫細胞癌療法
WO2019080538A1 (zh) 嵌合抗原受体、其修饰的NK细胞、编码 DNA、mRNA、表达载体、制备方法和应用
CN113454115A (zh) 靶向唾液酸化路易斯a的嵌合抗原受体及其用途
EP4294822A1 (en) Enhancing metabolic fitness of t cells to treat cancer
US20230355762A1 (en) Compositions and methods for the treatment of cancer using next generation engineered t cell therapy
Konagai et al. Correlation between NKG2DL expression and antitumor effect of protein-bound polysaccharide-K in tumor-bearing mouse models
KR20150136818A (ko) Il-12를 발현하는 간엽 줄기세포를 포함하는 간암 치료용 조성물 및 이를 이용한 치료방법
WO2022020860A3 (en) Engineered t cells and tumor-infiltrating lymphocytes to increase tumor killing
WO2014017941A1 (ru) Многопрофильный промотор и его использование в генной терапии рака
Kim Development of Genetically Modified Tumor Cell Containing Co-stimulatory Molecule
CN114096670B (zh) 激活免疫系统的细胞和包含该细胞的药物组合物
Zheng Engineered outer membrane vesicles enhance solid tumor CAR-T cell therapy
WO2024097814A1 (en) Engineered t cells having altered pyruvate metabolism, methods for their production and use in therapy, e.g., for treatment of cancer or infection